---
document_datetime: 2025-12-02 05:53:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mepsevii.html
document_name: mepsevii.html
version: success
processing_time: 0.1064983
conversion_datetime: 2025-12-24 15:25:24.389519
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mepsevii

[RSS](/en/individual-human-medicine.xml/66267)

##### Authorised

This medicine is authorised for use in the European Union

vestronidase alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mepsevii](#news-on)
- [More information on Mepsevii](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Mepsevii is a medicine to treat mucopolysaccharidosis type VII (MPS VII, also known as Sly syndrome), an inherited disease caused by a lack of an enzyme needed to break down complex carbohydrates known as glycosaminoglycans (GAGs).

The disease leads to build up of GAGs in the body, which causes a wide range of problems, including joint stiffness, short stature, enlarged liver and spleen, hearing loss, cataract and delays in development.

MPS VII is rare, and Mepsevii was designated an 'orphan medicine' (a medicine used in rare diseases) on 21 March 2012.

Expand section

Collapse section

## How is Mepsevii used?

Mepsevii is given every two weeks as an infusion (drip) into a vein lasting 4 hours. The recommended dose for each infusion is 4 mg per kilogram of body weight. Before the infusion the patient is given antihistamine treatment to reduce the risk of allergic reactions.

The medicine can only be obtained with a prescription and should be given by an appropriately trained healthcare professional who can manage medical emergencies. Treatment should also be supervised by a healthcare professional with experience in the treatment of MPS VII.

For more information about using Mepsevii, see the package leaflet or contact your doctor or pharmacist.

## How does Mepsevii work?

Mepsevii is an enzyme replacement therapy that works by replacing the missing enzyme (beta-glucuronidase) in patients with MPS VII, helping to break down GAGs and stopping them building up in the body.

## What benefits of Mepsevii have been shown in studies?

Mepsevii has been shown to reduce the levels of GAGs in the body and reduce or stabilise symptoms in patients with MPS VII.

In a main study of 12 patients with MPS VII, patients treated with Mepsevii for 6 months had a 65% reduction in their urine levels of GAGs. In 11 out of 12 patients, symptoms, including those affecting vision and movement, improved or did not get worse.

## What are the risks associated with Mepsevii?

The most common side effects with Mepsevii (which may affect more than 1 in 10 people) are anaphylactic reaction (sudden, severe allergic reaction), urticaria (itchy rash) and swelling at the infusion site.

Mepsevii must not be used in patients who have ever had anaphylactic reaction to vestronidase alfa or any of the other ingredients of the medicine. For the full list of side effects and restrictions, see the package leaflet.

## Why is Mepsevii authorised in the EU?

Mepsevii reduces the levels of GAGs in the body and improves or at least stabilises the symptoms of MPS VII. In addition, most adverse reactions are mild to moderate in severity.

Although only a limited amount of data is available from clinical studies, the European Medicines Agency took into account the life-threatening and debilitating nature of MPS VII and the lack of authorised medicines. EMA decided that Mepsevii's benefits are greater than its risks and that it can be authorised for use in the EU.

Mepsevii has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Mepsevii due to the rarity of the disease and for scientific reasons. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Mepsevii?

Since Mepsevii has been authorised under exceptional circumstances, the company that markets Mepsevii will conduct a study to provide data on the long-term effectiveness and safety of Mepsevii as well as on the disease itself, including its progression and development of symptoms.

## What measures are being taken to ensure the safe and effective use of Mepsevii?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mepsevii have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Mepsevii are continuously monitored. Side effects reported with Mepsevii are carefully evaluated and any necessary action taken to protect patients.

## Other information about Mepsevii

Mepsevii received a marketing authorisation under exceptional circumstances valid throughout the EU on 23 August 2018.

Mepsevii : EPAR - Medicine overview

Reference Number: EMA/435402/2020

English (EN) (113.24 KB - PDF)

**First published:** 28/08/2018

**Last updated:** 13/10/2020

[View](/en/documents/overview/mepsevii-epar-medicine-overview_en.pdf)

Mepsevii : EPAR - Risk-management-plan summary

Adopted

English (EN) (100.61 KB - PDF)

**First published:** 28/08/2018

**Last updated:** 28/08/2018

[View](/en/documents/rmp-summary/mepsevii-epar-risk-management-plan-summary_en.pdf)

## Product information

Mepsevii : EPAR - Product Information

English (EN) (441.53 KB - PDF)

**First published:** 28/08/2018

**Last updated:** 28/06/2024

[View](/en/documents/product-information/mepsevii-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-871)

български (BG) (467.52 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/bg/documents/product-information/mepsevii-epar-product-information_bg.pdf)

español (ES) (352.84 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/es/documents/product-information/mepsevii-epar-product-information_es.pdf)

čeština (CS) (449.62 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/cs/documents/product-information/mepsevii-epar-product-information_cs.pdf)

dansk (DA) (375.09 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/da/documents/product-information/mepsevii-epar-product-information_da.pdf)

Deutsch (DE) (363.7 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/de/documents/product-information/mepsevii-epar-product-information_de.pdf)

eesti keel (ET) (380.67 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/et/documents/product-information/mepsevii-epar-product-information_et.pdf)

ελληνικά (EL) (414.41 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/el/documents/product-information/mepsevii-epar-product-information_el.pdf)

français (FR) (360.76 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/fr/documents/product-information/mepsevii-epar-product-information_fr.pdf)

hrvatski (HR) (463.46 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/hr/documents/product-information/mepsevii-epar-product-information_hr.pdf)

íslenska (IS) (348.13 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/is/documents/product-information/mepsevii-epar-product-information_is.pdf)

italiano (IT) (354.22 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/it/documents/product-information/mepsevii-epar-product-information_it.pdf)

latviešu valoda (LV) (395.12 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/lv/documents/product-information/mepsevii-epar-product-information_lv.pdf)

lietuvių kalba (LT) (405.92 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/lt/documents/product-information/mepsevii-epar-product-information_lt.pdf)

magyar (HU) (428.38 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/hu/documents/product-information/mepsevii-epar-product-information_hu.pdf)

Malti (MT) (435.65 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/mt/documents/product-information/mepsevii-epar-product-information_mt.pdf)

Nederlands (NL) (360.02 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/nl/documents/product-information/mepsevii-epar-product-information_nl.pdf)

norsk (NO) (336.86 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/no/documents/product-information/mepsevii-epar-product-information_no.pdf)

polski (PL) (432.35 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/pl/documents/product-information/mepsevii-epar-product-information_pl.pdf)

português (PT) (343.62 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/pt/documents/product-information/mepsevii-epar-product-information_pt.pdf)

română (RO) (415.93 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/ro/documents/product-information/mepsevii-epar-product-information_ro.pdf)

slovenčina (SK) (418.53 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/sk/documents/product-information/mepsevii-epar-product-information_sk.pdf)

slovenščina (SL) (414.54 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/sl/documents/product-information/mepsevii-epar-product-information_sl.pdf)

Suomi (FI) (383.52 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/fi/documents/product-information/mepsevii-epar-product-information_fi.pdf)

svenska (SV) (339 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/06/2024

[View](/sv/documents/product-information/mepsevii-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0040/G 26/06/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mepsevii : EPAR - All Authorised presentations

English (EN) (10.86 KB - PDF)

**First published:** 28/08/2018

**Last updated:** 28/08/2018

[View](/en/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-941)

български (BG) (52.13 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/bg/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.03 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/es/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_es.pdf)

čeština (CS) (46.61 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/cs/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (10.86 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/da/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (11.01 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/de/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (10.85 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/et/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (47.21 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/el/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_el.pdf)

français (FR) (10.88 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/fr/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (40.47 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/hr/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (10.86 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/is/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_is.pdf)

italiano (IT) (10.98 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/it/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.24 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/lv/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (42.46 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/lt/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (24.76 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/hu/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (51.89 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/mt/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (10.81 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/nl/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (10.84 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/no/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.14 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/pl/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_pl.pdf)

português (PT) (10.91 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/pt/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_pt.pdf)

română (RO) (47.62 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/ro/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (40.16 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/sk/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.35 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/sl/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (10.91 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/fi/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (10.89 KB - PDF)

**First published:**

28/08/2018

**Last updated:**

28/08/2018

[View](/sv/documents/all-authorised-presentations/mepsevii-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mepsevii Active substance vestronidase alfa International non-proprietary name (INN) or common name vestronidase alfa Therapeutic area (MeSH) Mucopolysaccharidosis VII Anatomical therapeutic chemical (ATC) code A16AB18

### Pharmacotherapeutic group

Enzymes

### Therapeutic indication

Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).

## Authorisation details

EMA product number EMEA/H/C/004438

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Ultragenyx Germany GmbH

Rahel-Hirsch-Str. 10

Opinion adopted 26/04/2018 Marketing authorisation issued 23/08/2018 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Mepsevii : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (150.53 KB - PDF)

**First published:** 25/03/2019

**Last updated:** 28/06/2024

[View](/en/documents/procedural-steps-after/mepsevii-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Mepsevii : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/505941/2018

English (EN) (136.56 KB - PDF)

**First published:** 28/08/2018

**Last updated:** 28/08/2018

[View](/en/documents/orphan-maintenance-report/mepsevii-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Mepsevii : EPAR - Public assessment report

Adopted

Reference Number: EMA/480950/2018

English (EN) (1.9 MB - PDF)

**First published:** 28/08/2018

**Last updated:** 28/08/2018

[View](/en/documents/assessment-report/mepsevii-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Mepsevii

Adopted

Reference Number: EMA/CHMP/383566/2018

English (EN) (68.36 KB - PDF)

**First published:** 29/06/2018

**Last updated:** 29/06/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-mepsevii_en.pdf)

#### News on Mepsevii

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-june-2018) 29/06/2018

#### More information on Mepsevii

- [EU/3/12/973 - orphan designation for treatment of mucopolysaccharidosis type VII (Sly syndrome)](/en/medicines/human/orphan-designations/eu-3-12-973)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/06/2024

## Share this page

[Back to top](#main-content)